Targeted PSMA Radionuclide Drug Conjugates Market Report 2026-2032: Addressing the Metastatic Prostate Cancer Treatment Challenge Through Precision Radioligand Platforms, Theranostic Pairing, and Integrated Radiopharmaceutical Infrastructure
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Targeted PSMA Radionuclide Drug Conjugates – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Targeted PSMA Radionuclide Drug Conjugates market, including market size, share, demand, industry development status, and forecasts for the next few years.
The treatment of advanced prostate cancer has been transformed by a therapeutic principle that elegantly exploits a biological vulnerability: prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein overexpressed on the surface of prostate cancer cells with expression levels that correlate with disease progression, provides a molecular target for the selective delivery of cytotoxic radiation directly to malignant tissue while largely sparing surrounding healthy organs. For urologic oncologists, nuclear medicine specialists, and healthcare systems managing the global burden of metastatic castration-resistant prostate cancer (mCRPC)—a disease state affecting hundreds of thousands of patients worldwide—targeted PSMA radionuclide drug conjugates represent a paradigm shift from the sequential application of systemic therapies toward mechanism-based, image-guided precision radiotherapy. This market research analyzes the technology evolution from beta-emitting 177Lu toward alpha-emitting 225Ac platforms, the manufacturing and isotope supply chain constraints, and the competitive dynamics defining an industry projected to expand from USD 1,994 million in 2025 to USD 3,402 million by 2032, at a CAGR of 7.6%, with commercial gross margins estimated in the range of 55-70%.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6451770/targeted-psma-radionuclide-drug-conjugates
Market Scale, Product Definition, and the Radioligand Therapy Paradigm
The global market for Targeted PSMA Radionuclide Drug Conjugates was estimated to be worth USD 1,994 million in 2025 and is projected to reach USD 3,402 million, growing at a CAGR of 7.6% from 2026 to 2032. This growth trajectory reflects the progressive clinical validation of PSMA-targeted radioligand therapy, the expansion from late-line mCRPC into earlier treatment settings, and the establishment of the specialized manufacturing and clinical infrastructure required for radiopharmaceutical delivery. Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting PSMA. These products are typically composed of three molecular components: a PSMA-targeting small molecule or peptidomimetic ligand that binds with high affinity to the extracellular domain of PSMA, a chelator that stably complexes the radioisotope preventing its release during systemic circulation, and a therapeutic radionuclide that delivers cytotoxic radiation at the tumor site. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, with Novartis’ Pluvicto (177Lu-PSMA-617) having received FDA approval in March 2022 and EMA approval subsequently, while alpha-emitting candidates such as 225Ac-based products remain largely in clinical development or early-stage application.
The PSMA radioligand therapy value chain exhibits a distinctive structure combining the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing. Upstream segments include targeting ligands and precursors requiring GMP synthesis, chelators optimized for specific radioisotope coordination chemistry, radioisotope production and purification—177Lu is produced through neutron irradiation of enriched 176Yb or 176Lu targets in nuclear reactors, while 225Ac is derived from thorium-229 decay chains requiring specialized radiochemical separation—sterile radiopharmaceutical filling in radiation-shielded isolators, and specialized cold-chain logistics with decay-clock pressure. Because these products combine high clinical value with complex manufacturing, isotope supply constraints, dedicated facility requirements, and time-sensitive distribution, gross margins are generally higher than those of conventional small-molecule drugs and standard injectables, with 2025 estimates in the 55-70% range for commercialized products.
Technology Evolution and Pipeline Dynamics
The targeted prostate cancer radiopharmaceuticals industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy—with the phase 3 PSMAfore trial demonstrating efficacy of 177Lu-PSMA-617 in pre-chemotherapy mCRPC patients—the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion. From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, established industrial infrastructure including reactor-based production capacity, and stronger commercialization foundation built on Pluvicto’s market experience.
Simultaneously, the targeted radionuclide therapy industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures addressing PSMA heterogeneity and resistance mechanisms, combination regimens integrating radioligand therapy with androgen receptor pathway inhibitors, immune checkpoint inhibitors, or DNA damage repair inhibitors, and earlier treatment settings including hormone-sensitive disease, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects—alpha particles deliver approximately 1,500 times the linear energy transfer of beta particles, producing densely ionizing radiation tracks that are highly lethal to tumor cells—and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios beyond PSMA toward additional tumor targets, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
Manufacturing Infrastructure and Competitive Dynamics
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the radiopharmaceutical manufacturing sector can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place substantially higher demands on isotope supply reliability, specialized manufacturing facilities with radiation shielding and cleanroom classifications, quality release testing requiring rapid analytical methods given the short shelf life dictated by isotope half-lives, time-sensitive distribution measured in hours from manufacture to patient administration, and hospital nuclear medicine capabilities including appropriate imaging equipment for patient selection through PSMA-PET scans. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks that minimize transit time from production to clinical sites, and increasing treatment-center coverage. Competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access.
Nevertheless, the nuclear oncology market still faces several structural constraints. Stable isotope supply—dependent on limited numbers of research reactors and processing facilities—the construction cycle of dedicated manufacturing capacity measured in years, and the availability of specialized treatment centers with appropriate nuclear medicine infrastructure remain practical bottlenecks to market expansion. The trajectory toward USD 3,402 million by 2032 reflects the sustained clinical validation of PSMA-targeted radioligand therapy, progressive expansion into earlier treatment lines, and the gradual build-out of radiopharmaceutical manufacturing and clinical infrastructure necessary for broader patient access.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
